-
1Academic Journal
Συγγραφείς: I. V. Sidorov, A. S. Fedorova, E. I. Konopleva, A. S. Sharlai, D. M. Konovalov, И. В. Сидоров, А. С. Федорова, Е. И. Коноплёва, А. С. Шарлай, Д. М. Коновалов
Συνεισφορές: The study was performed without external funding, Исследование проведено без спонсорской поддержки
Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 9, № 4 (2022); 102-106 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 9, № 4 (2022); 102-106 ; 2413-5496 ; 2311-1267
Θεματικοί όροι: недифференцированная круглоклеточная саркома, EWSR1::non-ETS, NFATC2, “Ewing-like” sarcomas, undifferentiated round-cell sarcoma, «юингоподобные» саркомы
Περιγραφή αρχείου: application/pdf
Relation: https://journal.nodgo.org/jour/article/view/889/786; Kobayashi H., Makise N., Shinozaki-Ushiku A., Ishibashi Y., Ikegami M., Kohsaka S., Ushiku T., Oda K., Miyagawa K., Aburatani H., Mano H., Tanaka S. Scapular Angiomatoid Fibrous Histiocytoma with EWSR1-CREB1 Fusion in an Adult Patient. Case Rep Orthop. 2021; 2021: 9434222. doi:10.1155/2021/9434222.; Kannadasan K., Shenoy V. K., Kengagsubbiah S., Kumar S., Sathyabhama V. Intraosseous myoepithelial carcinoma of mandible – a case report with clinical, radiological, histopathologic and immunohistochemical features. J Clin Diagn Res. 2014; 8 (8): ZD46–8. doi:10.7860/JCDR/2014/10174.4762.; Grünewald T. G. P., Cidre-Aranaz F., Surdez D., Tomazou E. M., de Álava E., Kovar H., Sorensen P. H., Delattre O., Dirksen U. Ewing sarcoma. Nat Rev Dis Primers. 2018; 4 (1): 5. doi:10.1038/s41572-018-0003-x.; Machado I., Yoshida A., Morales M. G. N., Abrahão-Machado L. F., Navarro S., Cruz J., Lavernia J., Parafioriti A., Picci P., Llombart-Bosch A. Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, “undiff erentiated small round cell tumors”. A clinicopathologic, immunophenotypic and molecular analysis. Ann Diagn Pathol. 2018; 34: 1–12. doi:10.1016/j.anndiagpath.2017.11.011.; Bode-Lesniewska B., Fritz C., Exner G. U., Wagner U., Fuchs B. EWSR1-NFATC2 and FUS-NFATC2 Gene Fusion-Associated Mesenchymal Tumors: Clinicopathologic Correlation and Literature Review. Sarcoma. 2019; 2019: 9386390. doi:10.1155/2019/9386390.; Wang G. Y., Thomas D. G., Davis J. L., Ng T., Patel R. M., Harms P. W., Betz B. L., Schuetze S. M., McHugh J. B., Horvai A. E., Cho S. J., Lucas D. R. EWSR1-NFATC2 Translocation-associated Sarcoma Clinicopathologic Findings in a Rare Aggressive Primary Bone or Soft Tissue Tumor. Am J Surg Pathol. 2019; 43 (8): 1112–22. doi:10.1097/PAS.0000000000001260.; Bridge J. A., Sumegi J., Druta M., Bui M. M., Henderson-Jackson E., Linos K., Baker M., Walko C. M., Millis S., Brohl A. S. Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019; 32 (11): 1593–604. doi:10.1038/s41379-019-0301-1.; Diaz-Perez J. A., Nielsen G. P., Antonescu C., Taylor M. S., Lozano-Calderon S. A., Rosenberg A. E. EWSR1/FUS-NFATC2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review. Hum Pathol. 2019; 90: 45–53. doi:10.1016/j.humpath.2019.05.001.; Szuhai K., IJszenga M., Tanke H. J., Taminiau A. H., de Schepper A., van Duinen S. G., Rosenberg C., Hogendoorn P. C. Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. Cancer Genet Cytogenet. 2007; 172 (1): 12–22. doi:10.1016/j.cancergencyto.2006.07.007.; Cohen J. N., Sabnis A. J., Krings G., Cho S. J., Horvai A. E., Davis J. L. EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma: a case report and review of the literature. Hum Pathol. 2018; 81: 281–90. doi:10.1016/j.humpath.2018.03.020.; Sadri N., Barroeta J., Pack S. D., Abdullaev Z., Chatterjee B., Puthiyaveettil R., Brooks J. S., Barr F. G., Zhang P. J. Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion. Virchows Arch. 2014; 465 (2): 233–9. doi:10.1007/s00428-014-1613-7.; Chougule A., Taylor M. S., Nardi V., Chebib I., Cote G. M., Choy E., Nielsen G. P., Deshpande V. Spindle and Round Cell Sarcoma With EWSR1-PATZ1 Gene Fusion: A Sarcoma With Polyphenotypic Differentiation. Am J Surg Pathol. 2019; 43 (2): 220–8. doi:10.1097/PAS.0000000000001183.; Watson S., Perrin V., Guillemot D., Reynaud S., Coindre J. M., Karanian M., Guinebretière J. M., Freneaux P., Le Loarer F., Bouvet M., Galmiche-Rolland L., Larousserie F., Longchampt E., Ranchere-Vince D., Pierron G., Delattre O., Tirode F. Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol. 2018; 245 (1): 29–40. doi:10.1002/path.5053.; Mastrangelo T., Modena P., Tornielli S., Bullrich F., Testi M. A., Mezzelani A., Radice P., Azzarelli A., Pilotti S., Croce C. M., Pierotti M. A., Sozzi G. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene. 2000; 19 (33): 3799–804. doi:10.1038/sj.onc.1203762.; Сидоров И. В. Саркома с альтерациями гена BCOR (BCOR-ITD) с изолированным поражением L3-позвонка у мальчика 8 лет / И. В. Сидоров [и др.] // Вопросы гематологии / онкологии и иммунотерапии в педиатрии. – 2022. – 21 (3): 84–9. doi:10.24287/1726-1708-2022-21-3-84-89.; The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours Soft Tissue and Bone Tumours, 5 th ed. Lyon: IARC Press; 2020.; Sbaraglia M., Righi A., Gambarotti M., Dei Tos A. P. Ewing sarcoma and Ewing-like tumors. Virchows Arch. 2020; 476 (1): 109–19. doi:10.1007/s00428-019-02720-8.; Antonescu C. Round cell sarcomas beyond Ewing: emerging entities. Histopathology. 2014; 64 (1): 26–37. doi:10.1111/his.12281.; Yau D. T. W., Chan J. K. C., Bao S., Zheng Z., Lau G. T. C., Chan A. C. L. Bone Sarcoma With EWSR1-NFATC2 Fusion: Sarcoma With Varied Morphology and Amplification of Fusion Gene Distinct From Ewing Sarcoma. Int J Surg Pathol. 2019; 27 (5): 561–7. doi:10.1177/1066896919827093.; Szuhai K., Ijszenga M., de Jong D., Karseladze A., Tanke H. J., Hogendoorn P. C. The NFATC2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res. 2009; 15 (7): 2259–68. doi:10.1158/1078-0432.CCR-08-2184.; Le Loarer F., Pissaloux D., Coindre J. M., Tirode F., Vince D. R. Update on Families of Round Cell Sarcomas Other than Classical Ewing Sarcomas. Surg Pathol Clin. 2017; 10 (3): 587–620. doi:10.1016/j.path.2017.04.002.; Charville G. W., Wang W. L., Ingram D. R., Roy A., Thomas D., Patel R. M., Hornick J. L., van de Rijn M., Lazar A. J. EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. Mod Pathol. 2017; 30 (9): 1312–20. doi:10.1038/modpathol.2017.49.; Toki S., Wakai S., Sekimizu M., Mori T., Ichikawa H., Kawai A., Yoshida A. PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours. Histopathology. 2018; 73 (4): 645–52. doi:10.1111/his.13689.; Kinkor Z., Vaneček T., Svajdler M. Jr., Mukenšnabl P., Veselý K., Baxa J., Kokavec M. Where does Ewing sarcoma end and begin – two cases of unusual bone tumors with t(20; 22)(EWSR1-NFATC2) alteration. Cesk Patol. 2014; 50 (2): 87–91. PMID: 24758504.; Le Loarer F., Baud J., Azmani R., Michot A., Karanian M., Pissaloux D. Advances in the classification of round cell sarcomas. Histopathology. 2022; 80 (1): 33–53. doi:10.1111/his.14547.; https://journal.nodgo.org/jour/article/view/889
-
2Academic Journal
Συγγραφείς: G. B. Sagoyan, Yu. M. Mareeva, V. Yu. Roshchin, N. S. Grachev, D. M. Konovalov, A. E. Druy, V. P. Bondarenko, M. A. Alekseev, G. S. Ovsyannikova, D. V. Litvinov, N. V. Zhukov, Г. Б. Сагоян, Ю. М. Мареева, В. Ю. Рощин, Н. С. Грачёв, Д. М. Коновалов, А. Е. Друй, В. П. Бондаренко, М. А. Алексеев, Г. С. Овсянникова, Д. В. Литвинов, Н. В. Жуков
Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 4 (2018); 86-93 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 4 (2018); 86-93 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-4
Θεματικοί όροι: кобиметиниб, ameloblastic fibrosarcoma, undifferentiated round cell sarcoma, transformation, BRAF V600E mutation, vemurafenib, cobimetinib, амелобластная фибросаркома, недифференцированная круглоклеточная саркома, трансформация, мутация BRAF V600E, вемурафениб
Περιγραφή αρχείου: application/pdf
Relation: https://journal.nodgo.org/jour/article/view/444/426; Adekeye E.O., Lavery K.M. Recurrent ameloblastoma of the maxillofacial region. Clinical features and treatment. J Maxillofac Surg 1986;14:153–7. PMID: 3459793.; Hayashi N., Iwata J., Masaoka N., Ueno H., Ohtsuki Y., Moriki T. Ameloblastoma of the mandible metastasizing to the orbit with malignant transformation. A histopathological and immunohistochemical study. Virchows Arch 1997;430(6):501–7. PMID: 9230916.; Kessler H.P. Intraosseous ameloblastoma. Oral Maxillofac Surg Clin North Am 2004;16(3):309–22. doi:10.1016/j.coms.2004.03.001.; Sweeney R.T., Clary A.C., Myers B.R., Biscocho J., Neahring L., Kwei K.A., Qu K., Gong X., Ng T., Jones C.D., Varma S., Odegaard J.I., Sugiyama T., Koyota S., Rubin B.P., Troxell M.L., Pelham R.J., Zehnder J.L., Beachy P.A., Pollack J.R., West R.B. Identifi cation of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 2014;46:722–5. doi:10.1038/ng.2986.; Shaikhi K., Neiders M., Chen F., Aguirre A. Morphological variants of ameloblastoma and their mimickers. NAJ Med Sci 2012;5(1):20–8. doi:10.7156/v5i1p020.; Rais R., El-Mofty S.K. Malignant Transformation of a Desmoplastic Ameloblastoma to Squamous Cell Carcinoma: A Case Report. Head and Neck Pathol 2018. [Epub ahead of print]. doi:10.1007/s12105-018-0946-y.; Nobusawa A., Sano T., Yokoo S., Oyama T. Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation of the p53 gene: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;118(5):e146–50. doi:10.1016/j.oooo.2014.03.02112.; Brown N.A., Rolland D.C., McHugh J.B. Weigelin H.C., Zhao L., Lim M.S., Elenitoba-Johnson K.S., Betz B.L. Activating FGFR2- RASBRAF mutations in ameloblastoma. Clin Cancer Res 2014;20:5517–26. doi:10.1158/1078-0432.CCR-14-1069.; Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010;399(3):313–7. doi:10.1016/j.bbrc.2010.07.092.; Tang X., Guo X., Sun L.Y., Ai Y., Yang X., Sun J.J., Wu J.R., Gao J. BRAF-V600E mutation and its clinical signifi cance in children with Langerhans cell histiocytosis. Zhongguo Dang Dai Er Ke Za Zhi 2018;20(4):290–4. PMID: 29658453.; Pappo A.S. Pediatric melanoma: the whole (genome) story. Am Soc Clin Oncol Educ Book 2014:e432–5. doi:10.14694/EdBook_ AM.2014.34.e432.; Wegert J., Vokuhl C., Collord G., Del Castillo Velasco-Herrera M., Farndon S. J., Guzzo C., Jorgensen M., Anderson J., Slater O., Duncan C., Bausenwein S., Streitenberger H., Ziegler B., Furtwängler R., Graf N., Stratton M.R., Campbell P.J., Jones D.T., Koelsche C., Pfi ster S.M., Mifsud W., Sebire N., Sparber-Sauer M., Koscielniak E., Rosenwald A., Gessler M., Behjati S. Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun 2018;9(1):2378. doi:10.1038/s41467-018-04650-6.; Dahiya S., Emnett R.J., Haydon D.H., Leonard J.R., Phillips J.J., Perry A., Gutmann D.H. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 2014;16(2):318–9. doi:10.1093/neuonc/not146.; Pakneshan S., Salajegheh A., Smith R.A., Lam A.K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013;45:346–56. doi:10.1097/PAT.0b013e328360b61d.; Kurppa K.J., Caton J., Morgan P.R., Ristimäki A., Ruhin B., Kellokoski J., Elenius K., Heikinheimo K. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 2014;232:492–8. doi:10.1002/path.4317.; Fregnani E.R., Perez D.E., Paes de Almeida O., Fonseca F.P., Soares F.A., Castro-Junior G., Alves F. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology 2017;70(3):473–84. doi:10.1111/his.13095.; Menzies A.M., Long G.V. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 2014;15(9):e371–e381. doi:10.1016/S1470-2045(14)70072-5.; Holderfi eld M., Deuker M.M., McCormick F., McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;7:455–67. doi:10.1038/nrc3760.; Ascierto P.A., Schadendorf D., Berking C., Agarwala S.S., van Herpen C.M., Queirolo P., Blank C.U., Hauschild A., Beck J.T., St-Pierre A., Niazi F., Wandel S., Peters M., Zubel A., Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14(3):249–56. doi:10.1016/S1470-2045(13)70024-X.; Tan S., Pollack J.R., Kaplan M.J., Colevas A.D., West R.B. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122(1):e5–7. doi:10.1016/j.oooo.2015.12.016.; Faden D.L., Algazi A. Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 2016;109(1). pii: djw190. doi:10.1093/jnci/djw190.; Heikinheimo К., Kurppa K.J., Elenius K. Novel Targets for the Treatment of Ameloblastoma. J Dent Res 2015;94(2):237–40. doi:10.1177/0022034514560373.; https://journal.nodgo.org/jour/article/view/444